Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 112 | 2024 | 17531 | 6.610 |
Why?
|
South Africa | 63 | 2024 | 1868 | 4.590 |
Why?
|
Refugees | 10 | 2022 | 615 | 2.410 |
Why?
|
Contraception | 4 | 2024 | 360 | 2.320 |
Why?
|
CD4 Lymphocyte Count | 27 | 2024 | 2586 | 2.310 |
Why?
|
Anti-HIV Agents | 23 | 2024 | 4558 | 1.870 |
Why?
|
Mobile Health Units | 4 | 2019 | 91 | 1.870 |
Why?
|
Mass Screening | 20 | 2019 | 5449 | 1.700 |
Why?
|
Continuity of Patient Care | 8 | 2021 | 1075 | 1.540 |
Why?
|
Ambulatory Care Facilities | 10 | 2024 | 937 | 1.460 |
Why?
|
Tuberculosis, Pulmonary | 7 | 2024 | 836 | 1.420 |
Why?
|
Cryptococcus | 3 | 2021 | 28 | 1.410 |
Why?
|
Antigens, Fungal | 3 | 2021 | 69 | 1.380 |
Why?
|
Beauty Culture | 2 | 2019 | 41 | 1.270 |
Why?
|
Tuberculosis | 9 | 2024 | 2009 | 1.220 |
Why?
|
AIDS Serodiagnosis | 4 | 2014 | 220 | 1.170 |
Why?
|
Uganda | 19 | 2024 | 1353 | 1.120 |
Why?
|
Point-of-Care Systems | 6 | 2021 | 1218 | 1.100 |
Why?
|
Sarcoma, Kaposi | 7 | 2024 | 376 | 1.080 |
Why?
|
Mycobacterium tuberculosis | 7 | 2019 | 1909 | 1.060 |
Why?
|
Lipopolysaccharides | 5 | 2018 | 2213 | 1.010 |
Why?
|
Chlamydia Infections | 3 | 2024 | 366 | 0.990 |
Why?
|
AIDS-Related Opportunistic Infections | 4 | 2020 | 663 | 0.970 |
Why?
|
Gonorrhea | 3 | 2024 | 355 | 0.960 |
Why?
|
Anti-Retroviral Agents | 12 | 2022 | 1786 | 0.950 |
Why?
|
Antiretroviral Therapy, Highly Active | 9 | 2024 | 1899 | 0.940 |
Why?
|
Diagnostic Tests, Routine | 4 | 2015 | 788 | 0.900 |
Why?
|
Patient Acceptance of Health Care | 10 | 2024 | 3230 | 0.850 |
Why?
|
Sexually Transmitted Diseases | 3 | 2024 | 668 | 0.850 |
Why?
|
Meningitis, Cryptococcal | 2 | 2021 | 65 | 0.760 |
Why?
|
Adult | 89 | 2025 | 223088 | 0.740 |
Why?
|
Health Knowledge, Attitudes, Practice | 5 | 2022 | 4055 | 0.730 |
Why?
|
Reagent Kits, Diagnostic | 3 | 2018 | 238 | 0.710 |
Why?
|
Internationality | 2 | 2018 | 1007 | 0.700 |
Why?
|
Contraceptive Agents | 1 | 2021 | 147 | 0.680 |
Why?
|
Social Support | 5 | 2022 | 2190 | 0.670 |
Why?
|
Community Health Services | 4 | 2021 | 657 | 0.650 |
Why?
|
Qualitative Research | 11 | 2024 | 3136 | 0.640 |
Why?
|
HIV Seropositivity | 4 | 2013 | 961 | 0.600 |
Why?
|
Female | 95 | 2025 | 396141 | 0.590 |
Why?
|
Focus Groups | 5 | 2024 | 1458 | 0.590 |
Why?
|
Viral Load | 7 | 2024 | 3385 | 0.580 |
Why?
|
Humans | 143 | 2025 | 765926 | 0.580 |
Why?
|
Acquired Immunodeficiency Syndrome | 4 | 2022 | 2204 | 0.570 |
Why?
|
Male | 87 | 2025 | 363815 | 0.570 |
Why?
|
Prevalence | 19 | 2024 | 15828 | 0.560 |
Why?
|
Comprehensive Health Care | 1 | 2016 | 123 | 0.500 |
Why?
|
Lost to Follow-Up | 2 | 2017 | 124 | 0.500 |
Why?
|
Public Sector | 1 | 2017 | 264 | 0.490 |
Why?
|
Prospective Studies | 31 | 2025 | 54807 | 0.490 |
Why?
|
Health Resources | 5 | 2014 | 950 | 0.490 |
Why?
|
Social Stigma | 7 | 2024 | 787 | 0.480 |
Why?
|
Maternal Mortality | 1 | 2018 | 310 | 0.480 |
Why?
|
Hair | 1 | 2018 | 509 | 0.470 |
Why?
|
Influenza Vaccines | 1 | 2022 | 780 | 0.470 |
Why?
|
HIV-1 | 8 | 2020 | 6945 | 0.470 |
Why?
|
Patient Transfer | 2 | 2019 | 789 | 0.470 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2020 | 4405 | 0.460 |
Why?
|
Cryptococcosis | 1 | 2015 | 99 | 0.460 |
Why?
|
Rural Population | 4 | 2024 | 2318 | 0.460 |
Why?
|
Young Adult | 35 | 2024 | 59857 | 0.450 |
Why?
|
Postpartum Period | 2 | 2018 | 1195 | 0.440 |
Why?
|
Case Management | 2 | 2021 | 276 | 0.430 |
Why?
|
Voluntary Programs | 3 | 2014 | 48 | 0.430 |
Why?
|
Geographic Information Systems | 1 | 2015 | 281 | 0.430 |
Why?
|
Medically Underserved Area | 1 | 2015 | 267 | 0.420 |
Why?
|
Sputum | 6 | 2018 | 513 | 0.420 |
Why?
|
Pregnancy Complications, Infectious | 3 | 2024 | 2184 | 0.410 |
Why?
|
Trichomonas Infections | 2 | 2023 | 41 | 0.410 |
Why?
|
HIV | 6 | 2022 | 1587 | 0.400 |
Why?
|
Delayed Diagnosis | 2 | 2022 | 452 | 0.400 |
Why?
|
Health Services Research | 2 | 2017 | 1811 | 0.400 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2014 | 335 | 0.390 |
Why?
|
Sexual Partners | 4 | 2024 | 804 | 0.380 |
Why?
|
Homosexuality, Male | 4 | 2024 | 1342 | 0.380 |
Why?
|
Forecasting | 1 | 2020 | 2936 | 0.370 |
Why?
|
Influenza, Human | 1 | 2022 | 1539 | 0.360 |
Why?
|
HIV Seroprevalence | 1 | 2011 | 89 | 0.360 |
Why?
|
Counseling | 4 | 2023 | 1551 | 0.350 |
Why?
|
Outpatients | 4 | 2021 | 1595 | 0.350 |
Why?
|
Delivery of Health Care | 7 | 2023 | 5364 | 0.340 |
Why?
|
Clinical Trials as Topic | 2 | 2018 | 8037 | 0.340 |
Why?
|
Behavior Therapy | 1 | 2015 | 886 | 0.330 |
Why?
|
Bacteriological Techniques | 1 | 2010 | 276 | 0.320 |
Why?
|
Adolescent | 29 | 2024 | 88811 | 0.320 |
Why?
|
Middle Aged | 38 | 2025 | 223016 | 0.310 |
Why?
|
Placenta Diseases | 2 | 2021 | 199 | 0.310 |
Why?
|
Health Services Accessibility | 4 | 2017 | 5509 | 0.310 |
Why?
|
Cohort Studies | 18 | 2025 | 41680 | 0.300 |
Why?
|
Sensitivity and Specificity | 9 | 2021 | 14643 | 0.290 |
Why?
|
Medical Assistance | 1 | 2008 | 108 | 0.290 |
Why?
|
Medication Adherence | 4 | 2024 | 2190 | 0.280 |
Why?
|
Attitude of Health Personnel | 1 | 2021 | 3928 | 0.280 |
Why?
|
RNA, Viral | 4 | 2015 | 2866 | 0.280 |
Why?
|
Kenya | 7 | 2024 | 758 | 0.280 |
Why?
|
Motivation | 2 | 2023 | 2018 | 0.280 |
Why?
|
Trust | 2 | 2022 | 532 | 0.270 |
Why?
|
Contact Tracing | 3 | 2024 | 274 | 0.260 |
Why?
|
Cross-Sectional Studies | 11 | 2024 | 26282 | 0.260 |
Why?
|
Patient Satisfaction | 3 | 2015 | 3477 | 0.260 |
Why?
|
Serologic Tests | 2 | 2019 | 382 | 0.250 |
Why?
|
Government Programs | 1 | 2007 | 278 | 0.250 |
Why?
|
Barbering | 1 | 2024 | 12 | 0.240 |
Why?
|
Family Characteristics | 2 | 2023 | 1001 | 0.230 |
Why?
|
Pregnancy | 13 | 2024 | 30230 | 0.230 |
Why?
|
Tuberculosis, Multidrug-Resistant | 1 | 2012 | 941 | 0.230 |
Why?
|
Needlestick Injuries | 1 | 2004 | 71 | 0.220 |
Why?
|
Hypothermia | 2 | 2022 | 190 | 0.210 |
Why?
|
Pilot Projects | 3 | 2024 | 8724 | 0.210 |
Why?
|
Blood Sedimentation | 2 | 2022 | 234 | 0.210 |
Why?
|
Subacute Care | 2 | 2023 | 184 | 0.200 |
Why?
|
Fibrin Fibrinogen Degradation Products | 2 | 2022 | 427 | 0.200 |
Why?
|
Feasibility Studies | 3 | 2018 | 5300 | 0.190 |
Why?
|
Pandemics | 6 | 2023 | 8721 | 0.190 |
Why?
|
Syphilis | 1 | 2024 | 243 | 0.180 |
Why?
|
Health Behavior | 1 | 2012 | 2649 | 0.180 |
Why?
|
Drug Users | 1 | 2022 | 133 | 0.180 |
Why?
|
Fluconazole | 1 | 2021 | 154 | 0.180 |
Why?
|
Placenta | 4 | 2023 | 1726 | 0.180 |
Why?
|
Directly Observed Therapy | 1 | 2021 | 139 | 0.170 |
Why?
|
Drug Resistance, Multiple, Bacterial | 2 | 2017 | 592 | 0.170 |
Why?
|
Systemic Inflammatory Response Syndrome | 2 | 2022 | 621 | 0.170 |
Why?
|
Africa South of the Sahara | 5 | 2024 | 751 | 0.170 |
Why?
|
Massachusetts | 5 | 2024 | 8882 | 0.170 |
Why?
|
Severity of Illness Index | 7 | 2021 | 15878 | 0.170 |
Why?
|
Biomarkers, Pharmacological | 1 | 2020 | 161 | 0.170 |
Why?
|
Interviews as Topic | 3 | 2024 | 2740 | 0.160 |
Why?
|
Thoracostomy | 1 | 2019 | 78 | 0.160 |
Why?
|
Pregnancy, Unwanted | 1 | 2018 | 24 | 0.160 |
Why?
|
Pharmacies | 1 | 2021 | 171 | 0.150 |
Why?
|
Puerperal Infection | 1 | 2018 | 46 | 0.150 |
Why?
|
Immunologic Tests | 1 | 2019 | 101 | 0.150 |
Why?
|
Socioeconomic Factors | 4 | 2019 | 7842 | 0.150 |
Why?
|
Retrospective Studies | 15 | 2023 | 81537 | 0.150 |
Why?
|
Substance Abuse, Intravenous | 1 | 2022 | 527 | 0.150 |
Why?
|
Asymptomatic Infections | 1 | 2019 | 136 | 0.150 |
Why?
|
Viremia | 2 | 2022 | 727 | 0.150 |
Why?
|
DNA, Bacterial | 2 | 2014 | 1476 | 0.140 |
Why?
|
Risk Factors | 15 | 2025 | 74850 | 0.140 |
Why?
|
Nigeria | 5 | 2020 | 782 | 0.140 |
Why?
|
Acinetobacter | 1 | 2017 | 39 | 0.140 |
Why?
|
Regression Analysis | 3 | 2016 | 6321 | 0.140 |
Why?
|
Radiography, Thoracic | 2 | 2024 | 1319 | 0.140 |
Why?
|
Cost-Benefit Analysis | 5 | 2022 | 5531 | 0.140 |
Why?
|
Acinetobacter Infections | 1 | 2017 | 74 | 0.130 |
Why?
|
Safety | 1 | 2021 | 1157 | 0.130 |
Why?
|
Hospitals, General | 1 | 2020 | 803 | 0.130 |
Why?
|
Antifungal Agents | 1 | 2021 | 769 | 0.130 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2022 | 615 | 0.130 |
Why?
|
Occupational Diseases | 1 | 2004 | 1456 | 0.130 |
Why?
|
Diabetes Mellitus | 3 | 2024 | 5889 | 0.130 |
Why?
|
Cephalosporins | 1 | 2017 | 200 | 0.130 |
Why?
|
Pneumothorax | 1 | 2019 | 392 | 0.130 |
Why?
|
Obesity | 4 | 2022 | 13082 | 0.130 |
Why?
|
Social Environment | 1 | 2020 | 1010 | 0.130 |
Why?
|
Patient Compliance | 3 | 2017 | 2693 | 0.120 |
Why?
|
Logistic Models | 4 | 2020 | 13273 | 0.120 |
Why?
|
Mental Disorders | 1 | 2015 | 6870 | 0.120 |
Why?
|
Educational Status | 1 | 2023 | 2510 | 0.120 |
Why?
|
Proportional Hazards Models | 2 | 2020 | 12529 | 0.120 |
Why?
|
Aged | 16 | 2025 | 171163 | 0.120 |
Why?
|
Prenatal Care | 1 | 2022 | 1158 | 0.120 |
Why?
|
Random Allocation | 1 | 2019 | 2394 | 0.120 |
Why?
|
Disclosure | 1 | 2020 | 756 | 0.120 |
Why?
|
Odds Ratio | 4 | 2020 | 9656 | 0.120 |
Why?
|
Public-Private Sector Partnerships | 1 | 2015 | 123 | 0.120 |
Why?
|
Violence | 1 | 2020 | 931 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2024 | 10380 | 0.110 |
Why?
|
Income | 1 | 2023 | 1874 | 0.110 |
Why?
|
Interpersonal Relations | 1 | 2021 | 1432 | 0.110 |
Why?
|
Primary Health Care | 2 | 2021 | 4736 | 0.110 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2019 | 614 | 0.110 |
Why?
|
Geography | 2 | 2013 | 651 | 0.110 |
Why?
|
Vascular Diseases | 1 | 2021 | 1161 | 0.110 |
Why?
|
United States | 9 | 2025 | 72909 | 0.100 |
Why?
|
Caregivers | 2 | 2017 | 2304 | 0.100 |
Why?
|
Immunoenzyme Techniques | 2 | 2019 | 1695 | 0.100 |
Why?
|
Streptomycin | 1 | 2012 | 69 | 0.100 |
Why?
|
Patient Discharge | 2 | 2023 | 3460 | 0.100 |
Why?
|
Kanamycin | 1 | 2012 | 63 | 0.100 |
Why?
|
Depression | 1 | 2012 | 8223 | 0.100 |
Why?
|
Guidelines as Topic | 2 | 2010 | 1394 | 0.100 |
Why?
|
Ethambutol | 1 | 2012 | 59 | 0.100 |
Why?
|
Sex Factors | 3 | 2025 | 10611 | 0.100 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2020 | 949 | 0.100 |
Why?
|
Drug Monitoring | 1 | 2018 | 960 | 0.100 |
Why?
|
Hepatitis C | 1 | 2022 | 1596 | 0.100 |
Why?
|
Bayes Theorem | 1 | 2020 | 2353 | 0.100 |
Why?
|
C-Reactive Protein | 2 | 2022 | 3851 | 0.100 |
Why?
|
Chi-Square Distribution | 1 | 2018 | 3430 | 0.100 |
Why?
|
Reproducibility of Results | 3 | 2021 | 20133 | 0.100 |
Why?
|
Urinalysis | 1 | 2014 | 369 | 0.100 |
Why?
|
Public Health Administration | 1 | 2013 | 242 | 0.090 |
Why?
|
Inflammation | 2 | 2021 | 10843 | 0.090 |
Why?
|
Hospitals, Rural | 1 | 2012 | 175 | 0.090 |
Why?
|
Gene Products, gag | 1 | 2011 | 317 | 0.090 |
Why?
|
Algorithms | 3 | 2018 | 14064 | 0.090 |
Why?
|
Isoniazid | 1 | 2012 | 279 | 0.090 |
Why?
|
Stereotyping | 1 | 2012 | 242 | 0.090 |
Why?
|
Antitubercular Agents | 2 | 2019 | 1380 | 0.090 |
Why?
|
Hospitals, Urban | 1 | 2012 | 494 | 0.090 |
Why?
|
Rifampin | 1 | 2012 | 350 | 0.090 |
Why?
|
Intensive Care Units | 2 | 2021 | 3799 | 0.090 |
Why?
|
Disease Transmission, Infectious | 1 | 2015 | 560 | 0.080 |
Why?
|
Vulnerable Populations | 1 | 2015 | 717 | 0.080 |
Why?
|
Hospital Mortality | 2 | 2020 | 5339 | 0.080 |
Why?
|
Vaccination | 1 | 2022 | 3430 | 0.080 |
Why?
|
Drug Administration Routes | 1 | 2010 | 152 | 0.080 |
Why?
|
Health Care Surveys | 1 | 2017 | 2426 | 0.080 |
Why?
|
False Negative Reactions | 1 | 2011 | 570 | 0.080 |
Why?
|
Program Evaluation | 2 | 2015 | 2502 | 0.080 |
Why?
|
Hospitalization | 5 | 2021 | 10810 | 0.080 |
Why?
|
Cytokines | 1 | 2024 | 7417 | 0.080 |
Why?
|
Multivariate Analysis | 4 | 2018 | 12059 | 0.080 |
Why?
|
Inpatients | 1 | 2020 | 2563 | 0.080 |
Why?
|
Incidence | 4 | 2023 | 21513 | 0.080 |
Why?
|
Developing Countries | 2 | 2012 | 2913 | 0.080 |
Why?
|
Cell Count | 1 | 2013 | 1823 | 0.080 |
Why?
|
Child | 8 | 2022 | 80568 | 0.080 |
Why?
|
Ambulatory Care | 2 | 2011 | 2778 | 0.080 |
Why?
|
Prejudice | 1 | 2012 | 567 | 0.080 |
Why?
|
Medical Record Linkage | 1 | 2010 | 286 | 0.070 |
Why?
|
Mortality | 1 | 2019 | 2910 | 0.070 |
Why?
|
Referral and Consultation | 3 | 2020 | 3615 | 0.070 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2011 | 825 | 0.070 |
Why?
|
Monitoring, Physiologic | 1 | 2015 | 1793 | 0.070 |
Why?
|
International Cooperation | 1 | 2013 | 1433 | 0.070 |
Why?
|
Follow-Up Studies | 4 | 2019 | 39228 | 0.070 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 3247 | 0.070 |
Why?
|
Infant, Newborn | 6 | 2023 | 26380 | 0.070 |
Why?
|
Communication | 1 | 2020 | 3908 | 0.070 |
Why?
|
Peer Group | 2 | 2023 | 702 | 0.070 |
Why?
|
Staining and Labeling | 1 | 2010 | 1072 | 0.070 |
Why?
|
Ultrasonography | 1 | 2019 | 5987 | 0.060 |
Why?
|
Urban Health | 1 | 2008 | 531 | 0.060 |
Why?
|
Substance-Related Disorders | 1 | 2022 | 4418 | 0.060 |
Why?
|
Infant | 4 | 2022 | 36426 | 0.060 |
Why?
|
Survival Analysis | 2 | 2019 | 10086 | 0.060 |
Why?
|
Microscopy | 1 | 2010 | 900 | 0.060 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2007 | 391 | 0.060 |
Why?
|
Health Personnel | 2 | 2012 | 3385 | 0.060 |
Why?
|
Urban Population | 1 | 2012 | 2040 | 0.060 |
Why?
|
Self Care | 1 | 2009 | 800 | 0.060 |
Why?
|
Confidence Intervals | 1 | 2010 | 2915 | 0.060 |
Why?
|
Health Care Costs | 2 | 2014 | 3241 | 0.060 |
Why?
|
World Health Organization | 1 | 2010 | 1326 | 0.060 |
Why?
|
Age Factors | 3 | 2020 | 18382 | 0.050 |
Why?
|
Clinical Competence | 1 | 2019 | 4855 | 0.050 |
Why?
|
Hospitals | 1 | 2017 | 3886 | 0.050 |
Why?
|
Patient Education as Topic | 1 | 2013 | 2331 | 0.050 |
Why?
|
Acute Disease | 2 | 2011 | 7236 | 0.050 |
Why?
|
Europe | 1 | 2010 | 3430 | 0.050 |
Why?
|
Blotting, Western | 1 | 2011 | 5019 | 0.050 |
Why?
|
Electronic Health Records | 1 | 2020 | 4863 | 0.050 |
Why?
|
Blood Pressure | 1 | 2019 | 8530 | 0.050 |
Why?
|
Fever | 2 | 2022 | 1607 | 0.050 |
Why?
|
New Mexico | 1 | 2022 | 80 | 0.050 |
Why?
|
RNA | 2 | 2023 | 2716 | 0.050 |
Why?
|
Treatment Outcome | 4 | 2024 | 65194 | 0.050 |
Why?
|
Quality Indicators, Health Care | 1 | 2012 | 1804 | 0.050 |
Why?
|
Decision Trees | 1 | 2004 | 509 | 0.050 |
Why?
|
Tetanus Toxoid | 1 | 2022 | 186 | 0.050 |
Why?
|
Disease Progression | 2 | 2023 | 13614 | 0.050 |
Why?
|
Asthma | 1 | 2020 | 6268 | 0.050 |
Why?
|
Aged, 80 and over | 4 | 2022 | 59496 | 0.050 |
Why?
|
Self Report | 1 | 2013 | 3768 | 0.050 |
Why?
|
Bleomycin | 1 | 2022 | 491 | 0.050 |
Why?
|
Bacterial Proteins | 1 | 2014 | 3829 | 0.050 |
Why?
|
Polymerase Chain Reaction | 1 | 2010 | 6058 | 0.050 |
Why?
|
Hypertension | 2 | 2019 | 8616 | 0.050 |
Why?
|
Child, Preschool | 4 | 2022 | 42510 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2020 | 5836 | 0.040 |
Why?
|
Etoposide | 1 | 2022 | 636 | 0.040 |
Why?
|
Decision Making | 1 | 2014 | 3955 | 0.040 |
Why?
|
Cytomegalovirus Infections | 1 | 2007 | 837 | 0.040 |
Why?
|
Postnatal Care | 1 | 2022 | 273 | 0.040 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 15401 | 0.040 |
Why?
|
Longitudinal Studies | 3 | 2023 | 14745 | 0.040 |
Why?
|
Vincristine | 1 | 2022 | 1037 | 0.040 |
Why?
|
Sirolimus | 1 | 2007 | 1541 | 0.040 |
Why?
|
Boston | 2 | 2024 | 9334 | 0.040 |
Why?
|
Parity | 1 | 2022 | 931 | 0.040 |
Why?
|
Receptors, IgG | 1 | 2022 | 559 | 0.040 |
Why?
|
Drug Resistance, Viral | 1 | 2004 | 867 | 0.040 |
Why?
|
Internship and Residency | 1 | 2019 | 5945 | 0.040 |
Why?
|
Ferritins | 1 | 2022 | 600 | 0.040 |
Why?
|
Infant, Small for Gestational Age | 1 | 2021 | 468 | 0.040 |
Why?
|
Prognosis | 4 | 2021 | 29890 | 0.040 |
Why?
|
Pediatrics | 1 | 2013 | 3609 | 0.040 |
Why?
|
Prescriptions | 1 | 2021 | 388 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2023 | 1729 | 0.040 |
Why?
|
Leukocyte Count | 1 | 2022 | 1605 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2011 | 4641 | 0.040 |
Why?
|
Fetal Growth Retardation | 1 | 2021 | 591 | 0.040 |
Why?
|
Research Design | 1 | 2013 | 6204 | 0.040 |
Why?
|
Fetal Blood | 1 | 2024 | 1365 | 0.040 |
Why?
|
Botswana | 1 | 2020 | 1057 | 0.030 |
Why?
|
Rwanda | 1 | 2019 | 671 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 2022 | 1077 | 0.030 |
Why?
|
Health Facilities | 1 | 2021 | 577 | 0.030 |
Why?
|
Antibodies, Bacterial | 1 | 2022 | 1473 | 0.030 |
Why?
|
Aftercare | 1 | 2022 | 915 | 0.030 |
Why?
|
Causality | 1 | 2022 | 1247 | 0.030 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2020 | 12235 | 0.030 |
Why?
|
Fatigue | 1 | 2023 | 1553 | 0.030 |
Why?
|
Temperature | 1 | 2022 | 2226 | 0.030 |
Why?
|
Time Factors | 5 | 2020 | 40097 | 0.030 |
Why?
|
Chronic Disease | 1 | 2011 | 9351 | 0.030 |
Why?
|
Comorbidity | 2 | 2020 | 10575 | 0.030 |
Why?
|
Birth Weight | 1 | 2023 | 2122 | 0.030 |
Why?
|
Paclitaxel | 1 | 2022 | 1726 | 0.030 |
Why?
|
Mozambique | 1 | 2014 | 55 | 0.030 |
Why?
|
Models, Theoretical | 2 | 2021 | 3560 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2022 | 1084 | 0.030 |
Why?
|
Graft vs Host Disease | 1 | 2007 | 3079 | 0.030 |
Why?
|
Drug Therapy, Combination | 1 | 2004 | 6306 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2021 | 1740 | 0.030 |
Why?
|
Immunosuppressive Agents | 1 | 2007 | 4213 | 0.030 |
Why?
|
Endemic Diseases | 1 | 2015 | 190 | 0.030 |
Why?
|
Lung | 2 | 2024 | 10046 | 0.030 |
Why?
|
Radiography | 1 | 2024 | 6941 | 0.030 |
Why?
|
Sexual Behavior | 1 | 2023 | 2192 | 0.030 |
Why?
|
ROC Curve | 1 | 2021 | 3612 | 0.030 |
Why?
|
Respiratory Insufficiency | 1 | 2020 | 1241 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2022 | 3225 | 0.020 |
Why?
|
Gene Products, nef | 1 | 2011 | 101 | 0.020 |
Why?
|
Infection Control | 1 | 2019 | 984 | 0.020 |
Why?
|
Enzyme-Linked Immunospot Assay | 1 | 2011 | 126 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2022 | 3213 | 0.020 |
Why?
|
Public Health | 1 | 2024 | 2680 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2021 | 3498 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2022 | 4555 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2016 | 2844 | 0.020 |
Why?
|
Dermatology | 1 | 2020 | 905 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2020 | 2726 | 0.020 |
Why?
|
Length of Stay | 1 | 2023 | 6486 | 0.020 |
Why?
|
Risk Assessment | 1 | 2010 | 24275 | 0.020 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2007 | 5752 | 0.020 |
Why?
|
Patient Readmission | 1 | 2023 | 3282 | 0.020 |
Why?
|
Biopsy | 1 | 2020 | 6766 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2016 | 4851 | 0.020 |
Why?
|
Mental Health | 1 | 2022 | 3272 | 0.020 |
Why?
|
Critical Illness | 1 | 2021 | 2749 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2004 | 7423 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2021 | 11196 | 0.020 |
Why?
|
Macrophages | 1 | 2020 | 5772 | 0.020 |
Why?
|
Demography | 1 | 2010 | 1640 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 2011 | 1666 | 0.010 |
Why?
|
Registries | 1 | 2021 | 8346 | 0.010 |
Why?
|
Smoking | 1 | 2021 | 9082 | 0.010 |
Why?
|
Life Expectancy | 1 | 2011 | 1247 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2020 | 10256 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2011 | 3158 | 0.010 |
Why?
|
Body Mass Index | 1 | 2020 | 13042 | 0.010 |
Why?
|
Aging | 1 | 2022 | 8725 | 0.010 |
Why?
|
Models, Statistical | 1 | 2014 | 5088 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 11858 | 0.010 |
Why?
|
Leukemia | 1 | 2007 | 1522 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2007 | 4859 | 0.010 |
Why?
|
Quality Improvement | 1 | 2012 | 3847 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2019 | 15802 | 0.010 |
Why?
|
Recurrence | 1 | 2007 | 8492 | 0.010 |
Why?
|
Animals | 1 | 2004 | 168735 | 0.010 |
Why?
|
Quality of Life | 1 | 2012 | 13463 | 0.010 |
Why?
|